Stock fact sheet · data as of
Telix Pharmaceuticals Limited (TLX): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · Australia · High Growth
Is TLX undervalued?
At 10.65 (close of 16 Oct 2026), TLX trades 200% over the GLS average fair value of 3.55, with 0 of 5 models above the price. The stock earns none of the Wheel Score's Value points at this price. That is a statement about price against trailing fundamentals, not about the company's prospects - the Wall Street View and the Growth tab on the Quote page carry the forward numbers.
The 5 models disagree widely: EPV gives 1.09 while GLS Growth gives 6.01. A spread that wide means the average is sensitive to which methods you trust; the model table below shows where each one lands, and the Quote page lets you switch any of them off.
The nightly engine files TLX under High Growth: revenue and earnings growing fast enough that the growth-based models carry the valuation.
Nine valuation models for TLX
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | 2.55 | -76% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 5.62 | -47% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 2.46 | -77% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 6.01 | -44% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 1.09 | -90% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | -1.93 | -118% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 18.00 | +69% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Financial health is weak: TLX passes 4 of the nine Piotroski tests. Our screens drop the stock at the health rule; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is low at 2.5 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.
Returns on capital are thin or negative - ROIC -0.8%, ROE -1.7%, ROA -0.6% - with debt at 1.12 times equity and negative free cash flow.
Telix Pharmaceuticals Limited pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Digital Product Sales 75%, Digital Product Lease And Maintenance 25% (quarter Q2 FY2019).
Institutional ownership scores 1/10, insider activity 10/10 and Congressional trading 5/10 on the GLS smart-money scales; the last recorded insider buy was on 7 Sep 2026.
| Piotroski F-score | 4 / 9 | ROIC | -0.8% |
|---|---|---|---|
| GLS Moat | 2.5 / 10 | ROE | -1.7% |
| Debt / equity | 1.12 | ROA | -0.6% |
| Free-cash-flow yield | -1.7% | Payout ratio | 0% |
| Institutions | 1 / 10 | Insiders · Congress | 10 · 5 / 10 |
Wheel Score 25: No options
TLX has no listed options in the nightly snapshot, so there is nothing to sell and the stock cannot be wheeled however good the business; the Wheel Score is capped at 39 and shown as "No options" (25 here). The valuation and quality numbers still apply to owning the shares outright.
Volume runs at 223k shares a day on a market cap of $3.6B, with a beta of 0.60 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 12 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 0 / 25 | -200% margin of safety | |
| Health | 9 / 20 | Piotroski 4/9 | |
| Moat | 4 / 15 | moat 2.5/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 12 / 20 | 223k shares/day, $3.6B cap, beta 0.60 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
No upcoming earnings date is recorded for TLX in the nightly calendar.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Telix Pharmaceuticals Limited by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics, Inc. | 29.10 | 7.81 | -273% | 54Fair | $3.7B |
| LEGN Legend Biotech Corporation | 19.80 | - | - | 45Weak | $3.7B |
| RLAY Relay Therapeutics, Inc. | 17.06 | - | - | 45Weak | $3.7B |
| TNGX Tango Therapeutics, Inc. | 22.19 | - | - | 43Weak | $3.7B |
| AMLX Amylyx Pharmaceuticals, Inc. | 27.65 | 2.30 | -1102% | 42Weak | $3.5B |
| ACAD Acadia Pharmaceuticals Inc. | 19.71 | 67.06 | +71% | 80Prime | $3.4B |
| TARS Tarsus Pharmaceuticals, Inc. | 72.29 | 31.76 | -128% | 42Weak | $3.4B |
| XENE Xenon Pharmaceuticals Inc. | 33.90 | 2.44 | -1290% | 45Weak | $3.3B |
| IDYA IDEAYA Biosciences, Inc. | 33.85 | - | - | 45Weak | $3.3B |
| VKTX Viking Therapeutics, Inc. | 25.47 | 1.03 | -2365% | 40Weak | $3.2B |
| ADPT Adaptive Biotechnologies Corporation | 25.58 | - | - | 45Weak | $4.1B |
| ABCL AbCellera Biologics Inc. | 12.68 | - | - | 45Weak | $4.1B |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about TLX
Is TLX undervalued right now?
No: at 10.65 the stock trades 200% above the GLS average fair value of 3.55 (data as of 16 Oct 2026), well beyond what trailing earnings, cash flow and book value support.
What is the Wheel Score of TLX and what does it mean?
TLX has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for TLX?
3.55 per share as of 16 Oct 2026 - the simple average of the 5 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Telix Pharmaceuticals Limited report earnings next?
No upcoming earnings date is recorded for TLX in our calendar as of 16 Oct 2026; the Calendars page is refreshed every morning.
Does TLX have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on TLX, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.